Market Overview

ATUM Receives Patent to Expand and Integrate Transposon Based Technologies for Protein Pharmaceutical Development


ATUM (formerly DNA2.0 Inc.), a pioneer in bioengineering solutions,
announce the issuance of patent No. 10,041,077 by the U.S. Patent and
Trademark Office (USPTO) for expanding the scope of Leap-In, the
company's innovative transposon-based tool. The patent entitled "DNA
vectors, transposons and transposases for eukaryotic genome
modification," covers configurations of vectors and vector elements
together with transposons and transposases for improved recombinant
protein expression in mammalian cell lines. This patent complements
previously patented tools in the Leap-In suite to expand the company's
focus on state-of-the-art mammalian protein and antibody production.

"Our transposon-, and transposase-based platform has direct applications
in recombinant protein expression, cell line development and cell/gene
therapy," said Claes Gustafsson, PhD, ATUM's Chief Commercial Officer.
"We have already seen strong interest from protein pharmaceutical
companies in our proprietary tools for transient and stable protein
production in mammalian hosts. Now more than ever, we are in a position
to apply our bioengineering tools to the entire spectrum of
bioengineering, from designing and building better genes, proteins and
pathways all the way to genomes."

"This key Leap-In patent validates the genome engineering platform we're
building," said Jeremy Minshull, PhD, CEO of ATUM. "We are committed to
expand our recombinant protein and antibody expression suite of tools
for both transient and stable mammalian protein production. Our unique
and expanding Leap-In transposon patent estate in combination with our
operational focus on our new state-of-the-art mammalian protein and
antibody production laboratory enable efficient industrial scale

ATUM currently has 21 issued US patents covering bioengineering of
genes, proteins, genomes and more.

About ATUM

ATUM is the leading bioengineering solutions provider, offering an
integrated pipeline of tools including gene design, optimization and
synthesis, expression vectors, and platforms for protein and cell line
engineering and production. ATUM explores novel applications for
synthetic genes and the synergy between efficient gene design and
protein optimization technologies. ATUM's tools and solutions are
fueling the transformation of biology from a discovery science to an
engineering discipline. The company is privately held and is
headquartered in Newark, California. For more information, please visit

View Comments and Join the Discussion!